Improving support for our patients across Australia.
3 February 2020
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for patients nationally.
The new MPA/MIA agreement will focus on the introduction of a Tele Health Nurse Pilot Program to provide better access of services for melanoma patients; increasing the capacity and expertise of MPA’s Peer to Peer volunteer facilitators and volunteer support staff; enhancing face to face support groups within NSW and integration of these into MPA’s national support network; and joint involvement in events including patient information sessions and MIA’s national Melanoma March campaign.
With survival rates continuing to improve, the need for this collaboration to strengthen the support services available to our patients and families, is, thankfully, even greater. ’ Victoria Beedle, CEO of Melanoma Patients Australia
Melanoma patients and their families throughout the Riverina region will also benefit from strengthened and sustained melanoma services with the merger of Amie St Clair and Melanoma Institute Australia. It will provide immediate benefits by doubling the level of services provided to melanoma patients in the Riverina, including increased capacity of the free melanoma nursing services, the establishment of clinical trials in Wagga Wagga, opportunities for melanoma patients within the region to contribute to MIA research, and melanoma education opportunities – both professional (GPs/Clinics) and communitybased through the SunSafe Student Ambassador program.
‘Our shared vision is zero deaths from melanoma, no matter where you live, and this is a fantastic opportunity to enhance the effective delivery of treatment and support services to melanoma patients in this region.’ Annette St Clair, Co-founder of Amie St Clair Melanoma Trust
MIA is also delighted to be merging with melanomaWA, providing increased resources dedicated to reducing the impact of melanoma in Western Australia.
The two highly respected organisations will be working together on a regional and national level regarding awareness, education, support, and research.’ Mr Martin Slabbert, Chairman melanomaWA
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.